bioRxivCancer Biology
Novel Conformation Specific Inhibitors of Activated GTPases reveal Ras-dependency of Patient-Derived Cancer Organoids
S. Wiechmann, P. Maisonneuve, B. M. Grebbin, M. Hoffmeister, M. Kaulich, H. Clevers, K. Rajalingam, I. Kurinov, H. F. Farin, F. Sicheri, A. Ernst
Abstract
The small GTPases H, K and NRas are molecular switches that are indispensable for the correct regulation of cellular proliferation and growth. Mutations in Ras are associated with cancer and result in unwanted activation of signaling processes caused by aberrant recruitment of downstream effector proteins. In this study, we have engineered variants of the Ras-binding domain (RBD) of CRAF kinase that bind with highly improved affinity the effector binding site of Ras. Structural characterization demonstrates how the engineered RBD variants outcompete effector binding and inhibit Ras signaling in cells leading to apoptosis, growth arrest and senescence. The optimized RBD variants provide new insights in Ras biology and enabled the functional stratification of Ras dependency in patient-derived colorectal cancer organoids. One sentence summaryInhibition of effector kinase binding to Ras induces senescence in non-tumorigenic cells and reveals Ras dependency in patient-derived cancer organoids.
- organism: human
- assay: organoid / primary culture
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models
Daniela Farias de Nóbrega, Logan C. Eiler, … Karim I. Budhwani·bioRxiv·Feb 25, 2025
- RAS specific protease Induces Irreversible Growth Arrest via p27 in several KRAS Mutant Colorectal Cancer cell lines
C. K. Stubbs, M. Biancucci, … K. J. F. Satchell·bioRxiv·Dec 8, 2020
- Remodeling of KRAS interactome induced by clinically relevant RAS inhibitors reveals convergent responses and a KRAS-mediated regulation of directional cell migration
Yang Yang, Charles Y. Cho, … Jacob R. Haling·bioRxiv·Nov 14, 2025
- Targeting a broad spectrum of KRAS-mutant cancers by hyperactivation-induced cell death
J. Lilja, J. Kaivola, … J. Ivaska·bioRxiv·Sep 21, 2022
- Kinetic Signatures of RAS-BRAF Engagement Reveal Isoform Selectivity, Oncogenic Amplification, and Mutation-Dependent Inhibitor Resistance
Sravani Malasani, Zhihong Wang·FEBS JournalPeer-reviewed·Oct 27, 2026
- Discovery of allosteric non-covalent KRAS inhibitors that bind with sub-micromolar affinity and disrupt effector binding
M. J. McCarthy, C. V. Pagba, … A. A. Gorfe·bioRxiv·Oct 11, 2018